Department of Critical Care Medicine, Zhejiang Hospital, Hangzhou, China.
Ann Palliat Med. 2021 Oct;10(10):10349-10359. doi: 10.21037/apm-21-747. Epub 2021 Aug 11.
For many years, airway pressure release ventilation (APRV) has been used to manage patients with lung conditions such as acute respiratory distress syndrome (ARDS). However, it is still unclear whether APRV improves outcomes in critically ill ARDS patients who have been admitted to an intensive care unit (ICU).
In this study, randomized controlled trials (RCTs) were used to compare the efficacy of APRV to traditional modes of mechanical ventilation. RCTs were sourced from PubMed, Cochrane, and Embase databases (the last dates from August 8, 2019). The Cochrane Handbook for Systematic Reviews of Interventions was used to assess the risk of bias. The relative risk (RR), mean difference (MD), and 95% confidence intervals (CI) were then determined. Article types such as observational studies, case reports, animal studies, etc., were excluded from our meta-analysis. In total, the data of 6 RCTs and 360 ARDS patients were examined.
Six studies with 360 patients were included, our meta-analysis showed that the mean arterial pressure (MAP) in the APRV group was higher than that in the traditional mechanical ventilation group (MD =2.35, 95% CI: 1.05-3.64, P=0.0004). The peak pressure (Ppeak) was also lower in the APRV group with a statistical difference noted (MD =-2.04, 95% CI: -3.33 to -0.75, P=0.002). Despite this, no significant beneficial effect on the oxygen index (PaO2/FiO2) was shown between the two groups (MD =26.24, 95% CI: -26.50 to 78.97, P=0.33). Compared with conventional mechanical ventilation, APRV significantly improved 28-day mortality (RR =0.66, 95% CI: 0.47-0.94, P=0.02).
All the included studies were considered to have an unclear risk of bias. We determined that for critically ill patients with ARDS, the application of APRV is associated with an increase in MAP. Inversely, a reduction of the airway Ppeak and 28-day mortality was recorded. There was no sufficient evidence to support the idea that APRV is superior to conventional mechanical ventilation in improving PaO2/FiO2.
多年来,气道压力释放通气(APRV)一直用于治疗急性呼吸窘迫综合征(ARDS)等肺部疾病患者。然而,目前仍不清楚 APRV 是否能改善入住重症监护病房(ICU)的危重症 ARDS 患者的结局。
本研究使用随机对照试验(RCT)比较了 APRV 与传统机械通气模式的疗效。RCT 来自 PubMed、Cochrane 和 Embase 数据库(最后日期为 2019 年 8 月 8 日)。使用 Cochrane 干预系统评价手册评估偏倚风险。然后确定相对风险(RR)、均数差(MD)和 95%置信区间(CI)。我们的荟萃分析排除了观察性研究、病例报告、动物研究等文章类型。共检查了 6 项 RCT 和 360 名 ARDS 患者的数据。
纳入了 6 项研究共 360 名患者,我们的荟萃分析表明 APRV 组的平均动脉压(MAP)高于传统机械通气组(MD=2.35,95%CI:1.05-3.64,P=0.0004)。APRV 组的峰压(Ppeak)也较低,且具有统计学差异(MD=-2.04,95%CI:-3.33 至-0.75,P=0.002)。尽管如此,两组之间的氧指数(PaO2/FiO2)并没有显示出显著的有益效果(MD=26.24,95%CI:-26.50 至 78.97,P=0.33)。与常规机械通气相比,APRV 可显著降低 28 天死亡率(RR=0.66,95%CI:0.47-0.94,P=0.02)。
所有纳入的研究均被认为存在偏倚风险不确定。我们确定,对于患有 ARDS 的危重症患者,应用 APRV 与 MAP 升高相关。相反,气道 Ppeak 和 28 天死亡率降低。没有足够的证据支持 APRV 在改善 PaO2/FiO2 方面优于常规机械通气的观点。